Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ODN/Pam2 - Pulmotect

Next Previous
Drug Profile

ODN/Pam2 - Pulmotect

Alternative Names: ODN-M362/Pam2CSK4; Pam2-ODN; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pulmotect
  • Developer Cancer Prevention & Research Institute of Texas; National Heart, Lung and Blood Institute; Pulmotect; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antisense oligonucleotides; Antivirals; Lipopeptides
  • Mechanism of Action Toll like receptor 2 agonists; Toll like receptor 6 agonists; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; COVID 2019 infections
  • No development reported Haematological malignancies; Lung disorders; Pneumocystis pneumonia

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Lung-disorders in USA (Inhalation, Liquid)
  • 19 May 2023 Pharmacodynamics and adverse events data from a phase II trial in Chronic obstructive pulmonary disease presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
  • 25 Apr 2023 Pulmotect withdraws a phase I trial prior to enrollment for Haematologic malignancies in USA due to revision of development plan (NCT03097796)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top